|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Charlie_Kimball
gptkb:Novolog
gptkb:Levemir
|
|
gptkbp:acquisition
|
Apexian Pharmaceuticals (2021)
Zynerba Pharmaceuticals (2021)
|
|
gptkbp:awards
|
gptkb:Danish_Business_Award
Sustainability Award
Top Employer Award
Best Workplaces in Europe
Global Health Impact Award
|
|
gptkbp:ceo
|
gptkb:Lars_Fruergaard_Jørgensen
|
|
gptkbp:employees
|
approximately 45,000
|
|
gptkbp:founded
|
1923
|
|
gptkbp:headquarters
|
gptkb:Bagsværd,_Denmark
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Novo Nordisk
|
|
gptkbp:industry
|
gptkb:drug
|
|
gptkbp:market_cap
|
approximately 200 billion USD (2022)
|
|
gptkbp:partnership
|
gptkb:healthcare_organization
gptkb:Danish_Diabetes_Academy
gptkb:University_of_California,_San_Francisco
gptkb:World_Health_Organization
|
|
gptkbp:philanthropy
|
gptkb:Novo_Nordisk_Foundation
research funding
diabetes education programs
|
|
gptkbp:products
|
gptkb:Company
GLP-1 receptor agonists
growth hormones
obesity medications
hemophilia products
|
|
gptkbp:research_focus
|
gptkb:Company
obesity
cardiovascular diseases
chronic kidney disease
rare blood disorders
|
|
gptkbp:revenue
|
approximately 20 billion USD (2022)
|
|
gptkbp:specializes_in
|
diabetes care
obesity treatment
growth hormone therapy
hemophilia treatment
|
|
gptkbp:subsidiary
|
gptkb:Novo_Nordisk_A/_S
|
|
gptkbp:sustainability_initiatives
|
sustainable sourcing
carbon neutrality by 2030
waste reduction programs
Zero environmental impact by 2030
|
|
gptkbp:traded_on
|
gptkb:Copenhagen_Stock_Exchange
|
|
gptkbp:website
|
www.novonordisk.com
|